Enlivex Therapeutics Ltd. announced that on May 19, 2020, Executive Chairman, Mr. Shai Novik, voluntarily stepped-down from the Audit Committee and the Compensation Committee of the Company's Board of Directors (the "Board"), effective immediately, in light of the proposed amendment to the Company's agreement with Mr. Novik, as described in Proposal Two in the Proxy Statement. Mr. Novik remains a member of the Board. On May 19, 2020, the Board appointed Michel Habib as a member of the Audit Committee and Dr. Bernhard Kirschbaum as a member of the Compensation Committee, effective immediately. The Board has also determined that Mr. Habib is an "audit committee financial expert" under applicable U.S. Securities and Exchange Commission and Nasdaq rules. Currently, the Audit Committee is composed of Mr. Michel Habib, Dr. Avri Havron and Dr. Gili Hart, and the Compensation Committee is composed of Dr. Bernhard Kirschbaum, Dr. Avri Havron and Dr. Gili Hart. Dr. Avri Havron serves as Chair of the Audit Committee, and Dr. Gili Hart serves as Chair of the Compensation Committee.